ReviewMolecular psychiatry2025
Cannabinoid CB1 receptor-sensitive neurodevelopmental processes and trajectories.
Review in Molecular psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Towards a neurobiology of early intervention: the importance of critical periods for preventive psychiatry and youth mental health.Molecular psychiatry · 2026Review
- Is it safe-and ethical-to prescribe THC to youth?Psychopharmacology · 2026Article
- Beyond dopamine: Broader neuromodulatory contributions in sign- and goal-tracking.Psychopharmacology · 2026Review
- Cannabis and Psychosis: Genomic Methods Shed Light on Pathophysiological Processes.Biological psychiatry global open science · 2026Article
- Medical Cannabis During Pregnancy and Breastfeeding: Is the Concern Fully Evidence-Based?Biomedicines · 2026Article
- Altered reward-related resting-state network properties in adolescent cannabis use and depression.Progress in neuro-psychopharmacology & biological psychiatry · 2026Article
- ADHD Symptoms and Cannabis Use: The Role of Cannabinoid Receptor 1 and Neural Response Inhibition.medRxiv : the preprint server for health sciences · 2026Article
- Cannabinoid Therapies in Less-Common Disorders: Clinical Evidence and Formulation Strategies.Diseases (Basel, Switzerland) · 2026Review
- Rewired realities: novel insights into the neurobiology of cannabis use disorder and psychosis.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Article
- Multisystem regulation of reward and addiction: beyond the dopaminergic system.Frontiers in pharmacology · 2026Review
- Activation of cannabinoid receptor CB1 leads to aberrant myelination in development.bioRxiv : the preprint server for biology · 2025Article
- Prenatal Downregulation of CBThe Journal of neuroscience : the official journal of the Society for Neuroscience · 2025Article
- The CB1 receptor: linking impulsivity and substance use disorder.Frontiers in neuroscience · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
As high-potency cannabis (with high Δ
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.